Tracey Weisberg, M.D.

Board Member
Professional Title: 
Medical Director

With Maine Medical Center’s support, I have developed the multimodality Breast Care Center (BCC) at Maine Medical Center.  We convened Radiology, Radiation Therapy, Oncologic Surgery, Pathology, Plastic Surgery, Nursing, Rehab Medicine and Social Services to form an on-site clinic to evaluate and treat benign and malignant breast disease.  During this time, I developed the Breast Medical Genetics Program and then transitioned this to the Maine Medical Center Cancer Predisposition Clinic subsequently formed in 2004.  My current duties at the BCC include: oversight of medical affairs related to the BCC, oversight of weekly work rounds with BCC nursing staff, work with  administrative director to provide consultation on administrative oversight of the BCC, oversight of a weekly breast cancer tumor board with presentation of 4-8 new breast cancer patients, oversight of a quarterly BCC steering committee, provide direct patient consultations regarding utility of adjuvant/neoadjuvant chemo/hormonal therapy in management of  breast cancer and  provide access to clinical trials in management of breast cancer.  In addition, I am frequently asked to be a spokesperson to media on behalf of MMC regarding new developments in management of breast cancer.  Recent additional responsibilities have included organization of Maine Health focus groups to discuss implementation of cohesive screening guidelines and breast cancer treatment guidelines in Maine Health hospitals and oversight of application to become a certified breast care center.  Our most recent activity has been the establishment of a regional breast cancer tumor board.

I am also a Physician Owner of New England Cancer Specialists, a private practice of 14 Medical Oncologists in Southern Maine.  We are a QOPI certified Hematology and Oncology practice by the American Society of Clinical Oncology.   We are the first Commission on Cancer accredited Oncology Medical Home in Maine and one of the first 12 in the United States.  We were fortunate to be selected for the CMS Innovations project COME HOME.   We in July 2016 were awarded the CMS Oncology Care Model (OCM) designation. Through this federal program, we hope to be able to move to a 2-sided risk alternative payment model in 2019.

My personal practice has evolved to include 95% Breast cancer patients and 5% patients with other malignancies.  Additional responsibilities include teaching medical students and medicine house staff. 

In addition, I am the PI on over 50 breast cancer clinical trials that have been performed at New England Cancer Specialists over the years.

Boards and Committees